The 12th Annualsdbiomarkerssymposium.com/support/SDBiomarkers_2016...Thermo Fisher Scientific UC San Diego Health Zoll LifeVest _____ The 12th Annual Biomarkers in Heart Failure and

1

The 12th Annual

Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices

Friday, May 13, 2016Estancia La Jolla Hotel La Jolla, California

TABLE OF CONTENTSAcknowledgements (Educational Grants) ..........................................................................3Acknowledgements (Exhibitors) ........................................................................................4Course Information ..........................................................................................................5 Course Description, Objectives, Target Audience, Needs Assessment, Accreditation Statement, HFSA Statement, Cultural and Linguistic Competency Statement Faculty List ........................................................................................................................7Faculty Disclosures ............................................................................................................8Program ............................................................................................................................10Faculty Bios Program Director Alan Maisel, MD............................................................................................................11 Program Co-Director Lori Daniels, MD, FACC ..............................................................................................12 UC San Diego Participating Faculty Eric Adler, MD ..............................................................................................................13 Daniel Blanchard, MD, FACC ......................................................................................14 Ravindra L. Mehta, MBBS, MD, DM, FACP................................................................15 Sean-Xavier Neath, MD, PhD........................................................................................16 Pam R. Taub, MD, FACC ..............................................................................................17 Nicholas Wettersten, MD ..............................................................................................18 Guest Faculty Inder S. Anand, MD, PhD ..............................................................................................19 Christopher deFilippi, MD ............................................................................................20 Uri Elkayam, MD, FACC ..............................................................................................21 J. Thomas Heywood, MD ..............................................................................................22 Allan S. Jaffe, MD, FACC ............................................................................................23 John Kellum, MD ..........................................................................................................24 William Franklin Peacock, IV, MD, FACEP..................................................................25 Nicholas J. Schork, PhD ................................................................................................26 Alan Wu, PhD ................................................................................................................27

2

The 11th Annual


Friday, March 13, 2015Estancia La Jolla Hotel La Jolla, California

ACKNOWLEDGEMENTSWe would like to thank the following companies for their educational grants.

Their financial support has helped make this conference possible.

Abbott DiagnosticsAlere

DiadexusNovartis Pharmaceuticals Corporation

Ortho Clinical DiagnosticsOtsuka America Pharmaceuticals, Inc.

Relypsa, Inc.ResMed

Roche Diagnostics CorporationSingulex

St. Jude MedicalThermo Fisher Scientific

______________________

3

ACKNOWLEDGEMENTSWe would like to acknowledge the following companies and

organizations for exhibiting at this conference.

Actelion PharmaceuticalsBoehringer Ingelheim Pharmaceuticals

Boston ScientificCritical Diagnostics

DiadexusGilead Sciences

Janssen Pharmaceuticals, Inc.Maisel Lab

Mayo Medical LaboratoriesNovartis Pharmaceuticals CorporationOtsuka America Pharmaceuticals, Inc.

Prevencio, Inc.Relypsa, Inc.

ResMed sanofi

St. Jude MedicalThermo Fisher Scientific

UC San Diego HealthZoll LifeVest______________________

The 12th Annual



4

COURSE DESCRIPTIONThis annual event is designed to provide the latest clinical data, guidelines and evidence relatedto the clinical application of cardiac biomarkers. Topics cover state of the art application of bio-markers in the following clinical categories:• 2013 ACC/AHA guidelines and the integration of new biomarkers and new application ofexisting biomarkers

• Examination of the evolving utility of cardiac necrosis biomarkers in Acute CoronarySyndromes and Heart Failure

• Review of the latest clinical data associated with biomarkers in cardiovascular disease risk prediction and clinical management of disease.

• Integration of biomarker data in comorbid conditions including renal disease, diabetes and pulmonary disease

• The application of biomarkers in therapeutic and device trials as qualification criteria, surrogate endpoints, etc.

TARGET AUDIENCEThe target audience for this activity includes Cardiologists, Internists, Primary Care Physicians,Emergency Medicine Physicians, Clinical Laboratorians, Nursing Professionals and AlliedHealthcare Professionals.

OBJECTIVESAt the conclusion of this activity, participants should be able to:1. Describe the current standards of care associated with the application of biomarkers in cardiac clinical care.

2. Cite recent literature that provides an evidence-basis for the diagnostic, prognostic and management applications of cardiac biomarkers.

3. Discuss the future biomarker applications in cardiac disease based on breaking clinicalstudies and clinical trials.

4. Assess the effects of PCSK9 inhibition on various lipid biomarkers, and discuss their role in the management of dyslipidemia in various patient populations.

5. Apply biomarkers to help optimize selection of patients for cardiac devices, assess for response to device therapy, and improve prognostication of patients with devices.

6. Identify novel mobile technologies, applications, and devices that are impacting patient care and personalized medicine, and describe various ways they are being used.

NEEDS ASSESSMENTCardiovascular disease (CVD) is the leading cause of death in the United States and is responsiblefor 17% of national health expenditures. As the population ages, these costs are expected toincrease substantially. This program is intended to interpret the current standards of care associ-ated with the application of biomarkers in cardiac clinical care as well as review recent literaturethat provides evidence-basis for the diagnostic, prognostic and management application of car-diac biomarkers. continued

The 12th Annual



5

The diagnosis and management of cardiovascular conditions by clinical means alone is often inad-equate, including but not limited to heart failure. Until recently, biomarker testing in heart failure(HF) syndromes has been viewed as an elective supplement to diagnostic evaluation of patientssuspected to suffer from this condition. This approach to the use of biomarker testing contrastswith other cardiovascular diagnoses for which biomarkers are integral to disease process defini-tion, risk stratification, and in some cases treatment decision making. It is also noteworthy thatadvanced guidelines have emerged regarding the application of biomarkers in heart failure thatneed to be integrated into educational initiatives for clinical caregivers. There are emerging dataon the use of biomarkers to assist with patient selection for advanced therapies such as biventric-ular pacemakers, and to assist with therapy optimization and disease prognostication amongpatients with cardiac devices.In other related cardiovascular conditions such as acute coronary syndromes, biomarkers haveplayed a definitive diagnostic role yet confusion has evolved as the sensitivity of biomarkers suchas cardiac troponin has improved. These new and evolving issues are critical for clinicians to beprepared to interpret at the point of care.

ACCREDITATION STATEMENTThe University of California, San Diego School of Medicine is accredited by the AccreditationCouncil for Continuing Medical Education to provide continuing medical education for physicians.The University of California, San Diego School of Medicine designates this live activity for amaximum of 6.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit com-mensurate with the extent of their participation in the activity.For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRACategory 1 Credit(s)TM issued by organizations accredited by the ACCME. For the purpose of reli-censure, the California Board of Registered Nursing accepts AMA PRA Category 1 Credit(s)TM(report up to 6.5 hours of credit and list “CME Category 1” as the provider number).

HEART FAILURE SOCIETY OF AMERICAOfficially endorsed by the Heart Failure Society of America. The opinions presented in this edu-cational activity do not necessarily reflect the opinions or recommendations of the HFSA.

CULTURAL AND LINGUISTIC COMPETENCYThis activity is in compliance with California Assembly Bill 1195 which requires continuing medicaleducation activities with patient care components to include curriculum in the subjects of cultural and lin-guistic competency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skillsthat enables health care professionals or organizations to care effectively for patients from diverse cul-tures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeonto provide patients who do not speak English or who have limited ability to speak English, direct com-munication in the patient’s primary language. Cultural and linguistic competency was incorporated intothe planning of this activity. Additional resources on cultural and linguistic competency and informationabout AB1195 can be found on the UCSD CME website at http://cme.ucsd.edu.

6

The 12th Annual



FACULTY DISCLOSUREIt is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity and scientific rigor. All persons involved in theselection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an edu-cational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the indi-vidual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. Allpersons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from par-ticipating in the CME activity.

Eric Adler, MDAssociate Clinical ProfessorMedical Director, Cardiac Transplant

Daniel Blanchard, MD, FACCProfessor of Clinical MedicineDirector, UCSD Cardiology Fellowship Program

Inder S. Anand, MD, PhDProfessor of MedicineUniversity of MinnesotaMinneapolis, MN

Christopher deFilippi, MDVice-Chairman of Academic AffairsInova Heart and Vascular InstituteAdjunct Professor of Medicine, VCUFalls Church, VA

Uri Elkayam, MD, FACCProfessor of MedicineKeck School of MedicineUniversity of Southern CaliforniaLos Angeles, CA

Lori Daniels, MD, FACCProfessor of MedicineDirector, Coronary Care UnitDivision of CardiologyUC San Diego

UC SAN DIEGO PROGRAM CO-DIRECTORS

UC SAN DIEGO PARTICIPATING FACULTY

Alan Maisel, MD, FACCProfessor of CardiologyDirector: Coronary Care Unit andHeart Failure ProgramSan Diego Veterans Affairs Medical CenterUC San Diego

J. Thomas Heywood, MDMedical DirectorAdvanced Heart Failure and MechanicalCirculatory Support ProgramScripps HealthSan Diego, CA

Allan S. Jaffe, MD, FACCConsultantProfessor of MedicineChair, Core Clinical Laboratory Servicesin Laboratory Medicine and PathologyRochester, MN

John Kellum, MDProfessor and Vice Chair for ResearchDirector, Center for Critical Care NephrologyUniversity of PittsburghDepartment of Critical Care MedicinePittsburgh, PA

GUEST FACULTY

Ravindra L. Mehta, MBBS, MD,DM, FACPProfessor of Clinical MedicineUniversity of California, San Diego School of MedicineVice Chair Clinical Research, Department of MedicineDirector UCSD CREST and MAS inClinical Research Program

Sean-Xavier Neath, MD, PhDAssociate Clinical ProfessorDepartment of Emergency MedicineUniversity of California, San Diego

Pam R. Taub, MD, FACCAssociate Professor of MedicineDirector of Hannah and Gene StepCardiac WellnessAnd Rehabilitation CenterDivision of Cardiovascular Medicine

Nicholas Wettersten, MDFellowDepartment of Cardiology

William Franklin Peacock, IV,MD, FACEPProfessor, Emergency MedicineAssociate Chair and Research DirectorBaylor College of MedicineHouston, TX

Nicholas J. Schork, PhDProfessor and Director, Human BiologyJ. Craig Venter InstituteLa Jolla, CA

Alan Wu, PhDProfessor, of Laboratory MedicineUC San FranciscoSan Francisco, CA

7

The 12th Annual



!

It is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

Speaker Name Name of Commercial Interest Nature of Relevant Relationship

Employee, Grants/Research Support recipient, Board Member, Advisor or Review Panel member, Consultant, Independent Contractor, Stock Shareholder (excluding

mutual funds), Speakers’ Bureau, Honorarium recipient, Royalty recipient, Holder of Intellectual Property Rights,

or Other Eric Adler, MD Thoratec, Inc. Consultant Daniel Blanchard, MD Pfizer, Inc.

Bristol Meyers Squibb Boehringer Ingelheim

Consultant Consultant Consultant

Lori Daniels, MD Critical Diagnostics Roche Diagnostics Alere

Travel Support for Conference Speaker’s Bureau Independent Contractor

Christopher de Filippi, MD Roche Diagnostics Siemens Healthcare Diagnostics Ortho Diagnostics Abbott Diagnostics Radiometer Critical Diagnostics Thermo Fisher Diadexus MedScape

Grants/Research Support Advisor or Review Panel Member Honorarium Recipient Grants/Research Support Recipient/Consultant Consultant Grants/Research Support Recipient Consulting/Honorarium Grant Recipient Consulting/Honorarium Consulting Consulting/Honorarium

Uri Elkayam, MD Otsuka America Pharmaceuticals, Inc. Research Grant J. Thomas Heywood, MD Actelion Pharmaceuticals

Medtronic St. Jude/Thoratec Pfizer, Inc. Biotronik

Speaker’s Bureau/Honorarium Recipient/Consultant Honorarium Recipient/Consultant/Research Grant Honorarium recipient/Consultant/Research Grant Honorarium Recipient Honorarium Recipient

Allan S. Jaffee, MD Beckman-Coulter Alere Critical Diagnostics Radiometer Amgen Roche Ortho Diagnostics Abbott Diagnostics Siemens ET Healthcare Trinity Dart Neuroscience Novartis

Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant

continued

DISCLOSURES

8

The 12th Annual



John Kellum, MD Astute Medical Alere Abbott

Consultant/Grant Support Consultant/Grant Support Consultant/Grant Support

Alan Maisel, MD Alan Maisel, MD, cont.

Alere Thermo Fisher Abbott Critical Diagnostics BG Medicine Sphingotec Nexus Novartis Brahms Cardero therapeutics

Consultant/Research Support/Speaker’s Bureau Research Support/Speaker’s Bureau Research Support Speaker’s Bureau Consultant/Speaker’s Bureau/Research Support Consultant Research Support Research Support Research Support/Speaker’s Bureau Co-Founder

Ravindra Mehta, MD Gambro Astute Am Pharma Eli Lilly Abbvie Spectral Ardea, Inc. Grifols, Inc. Baxter, Inc. Ferring Research Fresenius Kabi ISIS Spingotec Johnson & Johnson Relypsa

Consultant Advisory Board Advisory Board Advisory Board Advisory Board Clinical Trial Advisor or Review Panel Member Grants/Research Support Recipient Consultant Consultant Speaker for Internal Conference/Advisor Consultant Consultant Advisor Focus Group

Sean-Xavier Neath, MD Alere BBI Diadexus Hycor Orgenics Quidel

Consultant Consultant Consultant Consultant Consultant Consultant

Nicholas Schork, PhD MYi Diagnostic and Discovery Click Therapeutics, Inc. Assurex Health, Inc. NuMedii, Inc. Pathway Genomics, Inc AbbVie Human Longevity, Inc. Vision Gate, Inc. Persimmune, Inc. Central Europe Genomics Center Genentech

Board Member, Stock Shareholder Board Member, Stock Shareholder Scientific Advisory Board Member Scientific Advisory Board Member Scientific Advisory Board member Consultant Consultant Consultant Consultant Co-Founder, Board Member, Stock Shareholder, Acting CEO Consultant

Pam Taub, MD Amgen Sanofi/Regeneron

Speaker’s Bureau Speaker’s Bureau

Alan Wu, PhD Spingotec Scientific Advisory Board

The following have no relevant financial relationships to disclose:

Inder Anand, MD, Nicholas Wettersten, MD, Vicky Alt Klug, Patti Strasberg The CME staff, meeting planners, planning committee and CME committee reviewers do not have any relevant financial relationships to disclose. This educational activity may contain discussion of unlabeled and/or investigational uses of agents that are not approved by the FDA. Please consult the prescribing information for each product. The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, San Diego.

9

The 12th Annual



PROGRAM7:00-8:00am Registration/Coffee7:15-8:15am Breakfast - Pacifica Ballroom7:15-8:15am Additional Session* - Pacifica Ballroom8:15-8:20am Introductions and Welcome - Drs. Alan Maisel and Lori Daniels

SESSION I BIOMARKERS & THERAPEUTIC MANAGEMENT - Lori Daniels, MD (Session Chair)

8:20-8:50am State-of-the-Art: Biomarkers and Therapeutic Guidance - Alan Maisel, MD

8:50-9:05am Pulmonary Arterial Pressure as a Cardiovascular Biomarker - J. Thomas Heywood, MD

9:05-9:20am Heart Rate as a Cardiovascular Biomarker - Inder Anand, MD

9:20-9:35am Lipids and Advanced Lipid Profiles and Biomarkers - Pam Taub, MD

9:35-9:50am Potassium as a Cardiovascular Biomarker - W. Frank Peacock, MD

9:50-10:05am hsTroponin - Allan S. Jaffe, MD

10:05-10:30am Coffee Break/Visit Exhibits

10:30-10:45am Impact of Angiotensin Receptor Neprolysin Inhibition on Natriuretic Peptides Christopher DeFilippi, MD

10:45-11:00am ST2 as a Cardiovascular Biomarker - Lori Daniels, MD

11:00-11:15am Adrenomedullin as a Cardiovascular Biomarker - Sean Neath, MD

11:15-11:30am Chest Pain Protocols - W. Frank Peacock, MD

11:30-11:45am Hyponatremia as a Cardiovascular Biomarker - Uri Elkayam, MD

11:45-12:00pm Apnea Hypopnea as a Cardiovascular Biomarker - Alan Maisel, MD

12:00-12:30pm Panel Discussion - Lori Daniels, MD and Panel

12:30-1:55pm Lunch12:45-1:45pm Additional Session** - Pacifica Ballroom

SESSION II BIOMARKERS, THE KIDNEY AND THE HEART - Alan Maisel, MD (Session Chair)

1:55-2:10pm Acute Kidney Injury - Ravindra L. Mehta, MD

2:10-2:25pm Akinesis Results - Nicholas Wettersten, MD

2:25-2:40pm Novel Biomarker Panel Approach to Renal Assessment - John Kellum, MD

2:40-2:55pm Pro-enkephalin and Renal Disease - Alan Wu, PhD

2:55-3:15pm Panel Discussion - Alan Maisel, MD and Panel

3:15-3:35pm Coffee Break/Visit Exhibits

SESSION III SPECIAL STATE-OF-THE-ART PRESENTATIONS - Alan Maisel, MD (Session Chair)

3:35-3:50pm INR-No Need Anymore? - Daniel Blanchard, MD

3:50-4:05pm Biomarkers and Human Longevity: Genetics and Beyond - Nicholas J. Schork, PhD

4:05-4:20pm Mobile Technology and Apps for Personalized Patient Care - Pam Taub, MD

4:20-4:35pm Pulmonary Hypertension - Eric Adler, MD

4:35-4:50pm Facilitated Question and Answer4:50-5:00pm Program Conclusion - Alan Maisel, MD and Lori Daniels, MD

ADDITIONAL SESSIONS AVAILABLE:Please note, the following sessions are not part of the accredited educational activity (credit is not offered for attending).Optional to attend.

*7:15-8:15am Thrombosis: Afib An Exploration in Risk Reduction - Pacifica Ballroom

**12:45-1:45pm Management of Heart Failure With Reduced Ejection Fraction - Pacifica BallroomSuperiority of a Novel Therapy to a Standard of Care Medication

10

Alan Maisel, MD, FACCProfessor of Cardiology

Director: Coronary Care Unit and Heart Failure ProgramSan Diego Veterans Affairs Medical Center

UC San DiegoSan Diego, CA

Dr. Alan Maisel attended University of Michigan Medical School and did his cardiology training atthe University of California at San Diego. He is currently Professor of Medicine at the Universityand director of the coronary care unit and the heart failure program at the affiliated VeteransAffairs Medical Center. He is considered one of the world’s experts on cardiac biomarkers, and isgiven credit for ushering in the use of BNP levels in clinical practice around the world. He has over300 articles in print and a large clinical and basic science lab and is past associate editor of theJournal of the American College of Cardiology. He has been Principal Investigator on eight multi-center biomarker trials. Dr. Maisel is also a fixture at the medical school, where he has won count-less teaching awards from medical students as well as interns and residents. Dr. Maisel is currentlyan Associate Editor of the Journal of American College of Cardiology. He has published two med-ical novels and helps to raise five children, He gave up on sleep five years ago.

The 12th Annual



11

Lori B. Daniels, MD, MAS, FACCProfessor of Medicine

Director, Coronary Care UnitDivision of Cardiology

UC San DiegoSan Diego, CA

Dr. Lori Daniels is a cardiologist at the University of California, San Diego and Director of theCoronary Care Unit. She is a graduate of Harvard College in Cambridge, Massachusetts andHarvard Medical School in Boston, Massachusetts. She completed her internship and residencyat the University of California, San Diego Medical Center and subsequently served as ChiefResident in Internal Medicine there. She also completed her Fellowship in Cardiology at UCSDMedical Center, serving as Chief Fellow during her final year. She received a Masters of AdvancedStudies in Clinical Research, and is a Fellow of the American College of Cardiology.

Dr. Daniels is the recipient of an American Heart Association Postdoctoral Research Grant, anAmerican College of Cardiology/Guidant Foundation Research Grant in Women’s CardiovascularHealth, and an American Heart Association Scientist Development Grant. Her research interestsfocus on using biomarkers to assess cardiovascular risk in a variety of populations; she also studiescardiovascular outcomes in young adults with a childhood history of Kawasaki Disease, and coro-nary/pulmonary angiographic findings in patients with chronic thromboembolic pulmonaryhypertension.

The 12th Annual



12

Eric Adler, MDAssociate Clinical Professor

Medical Director, Cardiac TransplantUniversity of California, San Diego

San Diego, CA

Eric Adler was born in New York City, New York. He attended Northwestern University forUndergraduate Studies followed by Boston University where he received his MD in 2000. Whileat Boston University he was awarded the prestigious Sarnoff Fellowship for CadiovascularResearch. He completed his clinical training in internal medicine at the University of Washingtonand in Cardiovascular Disease at the Mount Sinai School of Medicine. From 2009-2011 he was anAssistant Professor at the Oregon Health and Science University and is currently an AssociateClinical Professor of Medicine and Medical Director of Cardiac Transplant at the University ofCalifornia, San Diego

Eric’s clinical interests are in the care of patients with advanced heart failure, mechanical circulato-ry support and cardiac transplantation. He has a strong interest in the use of palliation in heartfailure, and has written numerous review articles on the topic.

The focus of his laboratory is the use of pluripotent stem cells for the study and treatment of car-diovascular disease. In previous work he demonstrated the utility of these stem cells for the isola-tion of enriched populations of heart cells. These cells can be isolated from both mice andhumans, and improve cardiac function in animal models of myocardial infarction. He also devel-oped novel techniques for tracking these cells once they are injected into the body. More recentlyhe collaborated on projects whose focus is the creation of stem cell derived heart cells frompatients with inherited forms of cardiovascular disease. These cells retain essentially qualities ofthe patients from which they were derived. We believe these cells offer an unprecedented oppor-tunity to study human heart disease at a molecular level.

The 12th Annual



13

Daniel Blanchard, MD, FACCProfessor of Clinical MedicineDirector, UCSD CardiologyFellowship Program

University of California, San DiegoSan Diego, CA

Dr. Blanchard is a professor of medicine in the Division of Cardiovascular Medicine atUCSD. He is currently Director of the Cardiology Fellowship Program at UCSD. His clinicalinterests include general cardiology, echocardiography, and advanced cardiac imaging tech-niques. His research interests have focused on cardiac imaging in pulmonary hypertensionand right ventricular overload.

The 12th Annual



14

Ravindra L. Mehta, MBBS, MD, DM, FACPProfessor of Clinical MedicineUniversity of California,

San Diego School of MedicineVice Chair Clinical Research,Department of Medicine

Director UCSD CREST and MAS in Clinical Research ProgramUCSD Medical CenterSan Diego, CA

Dr Mehta is a Professor of Medicine in the Division of Nephrology and Associate Chair for ClinicalResearch in the Department of Medicine at University of California San Diego where he directsthe Acute Dialysis Program and the UCSD Masters in Clinical Research Program. He is an inter-nationally recognized expert in the field of acute kidney injury (AKI). He holds a patent for“Continuous Hemodialysis Using Citrate”. He has worked with the ISN in developing courses inclinical nephrology and dialysis techniques. He chairs the annual International CRRT Conferencethat is now in its 22nd year. He chaired the ISN Committee on AKI, is a founding member of theAcute Dialysis Quality Initiative (ADQI) and the Acute Kidney Injury network (AKIN). His researchhas informed the development of the RIFLE and AKIN diagnostic and staging criteria for AKI anddevelopment of KDIGO guidelines for AKI. He has been recognized as one of the Best Doctors inSan Diego and the US for several years. In 2008 he was recognized by the American Nephrologistsof Indian Origin and in March 2009 he was elected as a Fellow of the Royal College of Physiciansin the UK. He received the ISN Bywaters Award for lifetime achievement in AKI in April 2011. Hehas most recently been appointed as the Director of the ISN 0by25 initiative to eliminate prevent-able deaths from AKI by 2025. He has trained over 50 post-doctoral fellows, of whom 17 have car-ried out their research projects with him. He received the M.B.B.S. degree (1976) from theGovernment Medical School in Amritsar, India, and the M.D. (1979) and D.M. (1981) degreesfrom the Post Graduate Institute of Medical Education and Research in Chandigarh, India. He sub-sequently completed a nephrology fellowship at the University of Rochester in Rochester NewYork and obtained his boards in Internal Medicine (1986) and Nephrology (1988). He has beenon the faculty at San Diego since 1988.

The 12th Annual



15

Sean-Xavier Neath, MD, PhDAssociate Clinical Professor

Department of Emergency MedicineUniversity of California, San Diego

San Diego, CA

Dr. Neath his Ph.D. and M.D. degrees from the University of Chicago. He completed his internshipat Mercy Hospital in San Diego and his residency in Emergency Medicine at the University ofCalifornia, San Diego. Dr. Neath joined the faculty of the University of California San Diego in2001, where he is now Associate Clinical Professor in the Department of Emergency Medicine. Hisresearch interests include the application of novel biomarkers in the diagnosis and managementof acute medical conditions such as sepsis, heart disease, allergy and immunology. Dr. Neathserved as one of the co-principal investigators at the UCSD site for the BACH (Biomarkers in AcuteHeart Failure) trial, the largest natriuretic peptide acute failure study to date. He is a fellow of theAmerican College of Emergency Physicians and a member of American Heart Association. Dr.Neath is a recipient of the Society for Academic Emergency Medicine Award, and the Wayne C.Booth Prize for Excellence in Graduate Teaching from the University of Chicago. Sean was awardedthe American Red Cross “Real Heroes” award for humanitarian disaster relief work in Haiti afterthe earthquake of January 2010.

The 12th Annual



16

Pam R. Taub, MD, FACCAssociate Professor of Medicine

Director of Hannah and Gene Step Cardiac WellnessAnd Rehabilitation Center

Division of Cardiovascular MedicineSan Diego, CA

Dr. Pam Taub is an Associate Professor of Medicine in the Division of Cardiovascular Medicine atUC San Diego. She is the director of the Step Family Cardiac Wellness and Rehabilitation Centerthat will be located in the new UC San Diego Jacobs Medical Center opening in 2016.

The mission of the Center is to actively engage patients and the community in prevention of car-diovascular disease. The Center will be conducting research on biomarkers and other diagnostics,wearable/mobile technologies that can improve patient outcomes.

Dr. Taub's clinical practice focuses on preventive cardiology. She is active in clinical/translationalresearch and is funded by the National Institutes of Health, Department of Defense, and AmericanHeart Association. Her research focuses on biomarkers for cardiovascular risk factor stratificationand in the examining the effects of epicatechin (a compound present in dark chocolate) on mito-chondrial function/ cellular bioenergetics and exercise capacity in patients with heart failure anddiabetes. She utilizes skeletal muscle biopsy and cardiopulmonary exercise testing to study mito-chondrial function in patients with cardiac disease.

Dr. Taub received her medical degree at Boston University School of Medicine. She completed herinternal medicine residency at the University of Washington Medical Center in Seattle and her fel-lowship in cardiology at UC San Diego.

The 12th Annual



17

Nicholas Wettersten, MDFellow

Department of CardiologySan Diego, CA

Nicholas Wettersten is currently a fellow in Cardiovascular Medicine at the University of California,San Diego. He received his medical degree from the University of California, Davis and continuedon at UC Davis for his Internal Medicine training before coming to UC San Diego for his fellow-ship. His research interests include the use of biomarkers for the diagnosis, risk-stratification andmanagement of cardiovascular diseases with specific interests in cardiorenal syndrome and out-comes in heart failure. He will complete his fellowship in 2017 after which he will continue histraining in the Advanced Heart Failure Fellowship at UC San Diego.

The 12th Annual



18

Inder S. Anand, MD, PhDProfessor of MedicineUniversity of MinnesotaMinneapolis, MN

Inder Anand is Professor of Medicine in the Cardiovascular Division at the University of Minnesotaand was the Director of the Heart Failure Clinic at the VA Medical Center in Minneapolis tillDecember 2014 when he retired. He received his undergraduate education in India, and postgrad-uate training at Oxford University, England where he was a Rhodes Scholar. He trained as a clinicalcardiologist in London, and was a Clinical Senior Lecturer at the National Heart and Lung Institute,London, for 2 years. Thereafter, Dr. Anand worked at the Postgraduate Institute of MedicalEducation and Research, Chandigarh, India, where he made seminal contributions to the under-standing of salt and water retention in the syndrome of congestive heart failure. His research inter-ests included experimental and clinical heart failure, and high altitude medicine and physiology.He has been a principal investigator in over 80 clinical trials and presently serves on Steering andExecutive committees of several National and International clinical trials. He is member of the edi-torial board of several Journals and has authored over 360 peer-reviewed scientific publications,over 600 abstracts and has over 5,000 citations of his published work. He has received numeroushonors, scholarship and fellowships including the 2010 AACIO Life Time Achievement Award, the2011 Cardiology Society of India Life Time Achievement Award, the 2011 University of MinnesotaInnovation Award, and Honorary Fellowship of the Association of Physicians of India in 2014. In January2015, he moved to San Diego where he continues with his interest in heart failure clinical trials.

The 12th Annual



19

Christopher deFilippi, MDVice-Chairman of Academic AffairsInova Heart and Vascular InstituteAdjunct Professor of Medicine, VCU

Falls Church, VA

Dr. deFilippi has a long-term research interest in cardiac biomarkers for diagnosis and prognosisin cardiovascular disease. His recent focus has been interpreting the cross sectional associationswith sub clinical cardiovascular disease and long-term prognosis in asymptomatic populationsincluding those with renal disease and asymptomatic older adults. He is particularly interested indetermining whether biomarker levels in asymptomatic populations can be used to guide the effi-cacy of lifestyle modifications or simple pharmacologic interventions to prevent or delay the pro-gression to cardiovascular disease and death.

The 12th Annual



20

Uri Elkayam, MD, FACCProfessor of MedicineKeck School of Medicine

University of Southern CaliforniaLos Angeles, CA

Uri Elkayam, MD received his medical degree from the Tel-Aviv University, Israel, in 1973 and ispresently Professor of Medicine (Cardiology) at the University of Southern California in LosAngeles. He is a past member of the executive council and chairman of the corporate affairs com-mittee of the American Society of Cardiac Failure. Doctor Elkayam is a member of the editorialboards of the American Journal of Cardiology, JACC heart failure, Cardiology, Journal of cardiovas-cular pharmacology and Therapeutics and Cardiology in Review and a past member of the edito-rial boards of JACC and the Journal of Cardiac Failure. He is a fellow of the American College ofCardiology, American Heart Association and American College of chest physicians.

Doctor Elkayam’s research and clinical interests are in the areas of congestive heart failure, heartdisease and pregnancy, valvular heart disease, cardiomyopathies and cardiovascular pharmacology.He has been involved in more than 100 self initiated; NIH and industry funded research projectsand served in a leading position in numerous national and international multi-center studies. Heis the author or co-author on over 190 publications and over 80 book chapters and has the dis-tinction of being listed in Best Doctors in America and America's Top Doctors from 2001 to 2016and as one of the top 100 most influential Israelis in the U.S. in 2011 .

The 12th Annual



21

J. Thomas Heywood, MDMedical Director

Advanced Heart Failure and Mechanical Circulatory Support ProgramScripps HealthSan Diego, CA

Dr. Heywood is the Medical Director of the Advanced Heart Failure and Mechanical CirculatorySupport Program at Scripps Health in La Jolla, California. He also serves as Director of the HeartFailure Recovery and Research Program and Co Director of the Pulmonary HypertensionProgram. He is board certified in Internal Medicine, Cardiovascular Diseases, Advanced HeartFailure and Transplant Cardiology, and Echocardiography.

Previously, Dr. Heywood served as Director of the Adult Cardiac Transplantation Program andDirector of the Cardiomyopathy Program at Loma Linda University Medical Center. He also servedas Professor of Medicine at Loma Linda University School of Medicine.

Dr. Heywood has served on a variety of boards including the Advisory Council to ImproveOutcomes Nationwide in Heart Failure Consensus Recommendations for the Management ofChronic Heart Failure, the Board of Directors, American Heart Association, Inland Empire Chapter,and Board of Directors, Loma Linda Veterans Administration Research and Education among oth-ers. He has been a principle investigator in many pivotal heart failure trials and is very active inclinical heart failure research. He is the author of numerous articles, abstracts and book chapterson congestive heart failure. His most recent publication is “The Cardiorenal Syndrome: AClinician’s Guide to Pathophysiology and Management.”

Dr. Heywood received a degree in Theology at Loyola University, Chicago and a medical degreefrom the University of California, San Diego. He completed a residency in Internal Medicine inSan Diego followed by a cardiology fellowship at Loma Linda University Medical Center. After hiscardiology fellowship he spent a year as a cardiovascular research fellow at the University of Zurichin Zurich, Switzerland.

The 12th Annual



22

Allan S. Jaffe, MD, FACCConsultant

Professor of MedicineChair, Core Clinical Laboratory Services inLaboratory Medicine and Pathology

Rochester, MN

Dr. Allan Jaffe is a graduate of the University of Maryland School of Medicine. He received hishouse staff and Cardiology training at Washington University and continued there for 22 years ris-ing to the rank of Professor of Medicine and Director of the Coronary Care Unit. He then movedto the State University of New York where he was Chair of the Cardiovascular Division, AssociateChair of Medicine for Academic Affairs, and Professor of Medicine. After four years he moved tothe Mayo Clinic where he is presently Professor of Medicine in the Cardiovascular Division andProfessor and Chair of the Division of Core Clinical Laboratory Services in the Department ofLaboratory Medicine and Pathology. He is a noted authority on biomarkers of cardiac injury,inflammation, hemodynamic disturbance, and coagulation and particularly their clinical utility. Hehas published a large number of original manuscripts, book chapters, reviews, and sits on most ofthe prestigious editorial boards and guideline committees in the Cardiology and ClinicalChemistry communities.

The 12th Annual



23

John Kellum, MD, MCCMProfessor and Vice Chair for Research

Director, Center for Critical Care NephrologyUniversity of Pittsburgh

Department of Critical Care MedicinePittsburgh, PA

John A. Kellum, MD, MCCM is Professor of Critical Care Medicine, Medicine, Bioengineering andClinical and Translational Science, and Vice Chair for Research within the Department of CriticalCare Medicine and Director of the Center for Critical Care Nephrology at the University ofPittsburgh.

Dr. Kellum received his medical degree from the Medical College of Ohio in 1984. His postgrad-uate training includes an internship and residency in Internal Medicine at the University ofRochester, NY, and a Fellowship in Critical Care Medicine at the University of Pittsburgh MedicalCenter.

Dr. Kellum is actively involved in education, research and administration. Dr. Kellum’s researchinterests span various aspects of Critical Care Medicine, but center in critical care nephrology, sep-sis and multi-organ failure, and clinical epidemiology, including consensus development andresearch methodology. He has authored more than 275 publications and has won several awardsfor teaching. He lectures widely and has given more than 300 seminars and invited lectures world-wide related to his research.

The 12th Annual



24

William Franklin Peacock, IV, MD, FACEPProfessor, Emergency Medicine

Associate Chair and Research DirectorBaylor College of Medicine

Houston, TX

W. Frank Peacock IV, MD, FACEP is a Professor of Emergency Medicine, Associate Chair, andResearch Director for Emergency Medicine at the Baylor College of Medicine, in Houston, Texas. Heis currently on the Board of Directors, Chair of the publication committee, and has served as pastPresident of the Society of Cardiovascular Patient Care (formerly known as the Society for Chest PainCenters).

With over 400 peer reviewed publications on heart failure and acute coronary syndromes, Dr.Peacock is also the co-editor of the textbooks Cardiac Emergencies, Short Stay Management of HeartFailure, and Short Stay Management of Chest Pain. He is the 2004 and 2010 winner of the BestResearch Paper Award from the American College of Emergency Physicians, and is the CodmanAward recipient from the American Association of Group Practice.

Dr. Peacock has and continues to serve as PI or co-PI for many high profile national and internationalclinical trials such as PRONTO, ADHERE-EM, IMPACT, CHOPIN, CLUE, FASTTRACK, and TRUE-HF.Dr. Peacock’s research focus is that of cardiovascular emergency medicine, and includes acute coro-nary syndrome, acute heart failure, venous thromboembolic disease, atrial fibrillation, biomarkers,improvements in emergency medical care and more rapid patient disposition. Dr. Peacock receivedhis medical degree from Wayne State University Medical School and completed his EmergencyMedicine training at William Beaumont Hospital, Detroit, Michigan.

The 12th Annual



25

Nicholas J. Schork, PhDProfessor and Director, Human Biology

J. Craig Venter InstituteLa Jolla, CA

Dr. Schork is Professor and Director, Human Biology, at the J. Craig Venter Institute (JCVI),Professor at the Translational Genomics Research Institute (TGen) in Phoenix and an AdjunctProfessor at the University of California, San Diego. Prior to his position at the JCVI, Dr. Schorkwas a Professor, Molecular and Experimental Medicine, at The Scripps Research Institute (TSRI)and Director of Bioinformatics and Biostatistics for the Scripps Translational Science Institute(STSI). Dr. Schork has also held faculty appointments at Case Western Reserve University (CWRU)and Harvard University. Between 1999 and 2000 Dr. Schork took a leave of absence from CWRUto conduct research as the Vice President of Statistical Genomics at the French Biotechnologycompany, Genset, where he helped guide efforts to construct the first high-density map of thehuman genome. He has published over 500 articles in the area of the genetic dissection of com-plex phenotypes. These articles include both methodological and applied studies. He also has along history of collaborative and consortium-related research in which he has contributed analysismethodology and applied data analysis expertise. Dr. Schork has a number of patents associatedwith genetic analysis methodology, been involved with more than 10 start-up companies, and hasmentored over 75 students and post-doctoral fellows.

The 12th Annual



26

Alan Wu, PhDProfessor, of Laborary Medicine

UC San FranciscoSan Francisco, CA

Alan H.B. Wu, Ph.D., is Chief of Clinical Chemistry and Toxicology at San Francisco General Hospitaland Professor of Laboratory Medicine, University of California, San Francisco. He received B.S.degrees in chemistry and biology at Purdue University, West Lafayette, Indiana, and a Ph.D. degreein analytical chemistry at the University of Illinois, Champaign-Urbana, Illinois. He completed apostdoctoral fellowship in clinical chemistry at Hartford Hospital. He is certified by the AmericanBoard of Clinical Chemistry in Clinical Chemistry and Toxicological Chemistry. He has written fourbooks consisting of short stories designed to promote the value of the clinical laboratory to the gen-eral public.

The 12th Annual



27

Documents

The 12th Annualsdbiomarkerssymposium.com/support/SDBiomarkers_2016...Thermo Fisher Scientific UC San Diego Health Zoll LifeVest _____ The 12th Annual Biomarkers in Heart Failure and